Clinical Significance of Idiopathic Frequent Premature Ventricular Complexes

Login or register to view PDF.
Abstract

Premature ventricular complexes (PVCs) in the absence of underlying structural heart disease are often benign. Most patients with this type of disease have an uneventful clinical course and can be treated based on symptoms. However, there exists a subset of patients with frequent PVCs that may develop cardiomyopathy and heart failure. This review describes the mechanisms and potential adverse effects of frequent PVCs, the prognosis and risk stratification of patients based on the nature and quantity of PVCs, and the clinical management and outcomes of these patients.

Disclosure
The author has no conflict of interest to declare.
Correspondence
Rakesh Latchamsetty, MD, Cardiovascular Center, 1500 E Medical Center Dr SPC 5856, Ann Arbor, MI 48109-5856. E: rakeshl@med.umich.edu
Received date
26 August 2017
Accepted date
27 September 2017
Citation
US Cardiology Review 2017;11(2):95–7.
DOI
https://doi.org/10.15420/usc.2017:19:1

Introduction

Premature ventricular complexes (PVCs) in the absence of underlying structural heart disease have long been viewed as benign. Early studies with small population sizes and limited cardiac testing suggested that long-term prognosis in patients with idiopathic PVCs is similar to those in patients without other cardiac disease, and treatment was consequently limited to provide symptomatic improvement. While most patients with infrequent or moderate idiopathic PVCs have benign outcomes and can be managed based on symptoms, there exists a subset of patients with frequent PVCs that may develop cardiomyopathy and heart failure. Due to its rare occurrence, the nature and predictability of PVCs causing sudden cardiac death (SCD) is not well described and risk stratification and management of such patients remains a challenge. In this review, I first describe the mechanisms and potential adverse effects of frequent PVCs with a focus on the development of cardiomyopathy. I will subsequently discuss prognosis and risk stratification in patients based on the nature and quantity of PVCs. Finally, I will describe clinical management and outcomes.

Epidemiology and Mechanisms

The prevalence of PVCs in the population inherently depends on the type and duration of screening. In a study of 122,043 men in the United States Air Force monitored by EKG for 48 s, <1 % were noted to have PVCs.1 When monitoring was extended to 6 h in 301 men, 62 % had PVCs.2 A PVC burden of >60/h was reported in 1–4 % of the general population.3 The natural history of PVCs is incompletely understood and it is not clear why some patients have spontaneous resolution or improvement in PVCs, others have maintenance of their PVC burden without compromise of cardiac function, and others develop cardiomyopathy and heart failure even with similar PVC burdens or origins.

Initiation of PVCs can be due to any of the three primary arrhythmia mechanisms: re-entry, automaticity, or triggered activity. The autonomic nervous system also plays a significant role, and can affect PVC genesis due to automaticity or triggered activity in particular. Increased sympathetic tone can enhance automaticity in an ectopic focus or induce cAMP-mediated triggered activity.4 Vagal activity has been suggested to potentially facilitate early afterdepolarizations that can lead to increased ventricular arrhythmias.5 The influence of the autonomic nervous system was demonstrated in a recent analysis where idiopathic PVCs were identified as being either bradycardia or tachycardia dependent in 80 % of patients.5 This is evident in the variability of clinical presentation where some patients have exertional ventricular arrhythmia whereas others experience a higher PVC burden at rest. Treatment options are also affected, with patients demonstrating tachycardia-dependent PVCs being more likely to respond to sympatholytic therapies such as beta blockers.5

Prognosis

The prognosis in patients with frequent PVCs is affected by the presence of underlying cardiac disease. In patients with a recent myocardial infarction, the presence of frequent PVCs is associated with worse outcomes, including increased mortality.6 In these patients, based on failure to improve outcomes with attempts at PVC suppression,7 it is suspected that PVCs likely serve more as a marker of the severity of underlying disease rather than a modifiable risk factor.

In the absence of other cardiac disease, the prognosis of patients with frequent idiopathic PVCs is determined by a number of factors, including PVC frequency. A recent long-term prospective analysis over a mean follow-up of 13 years showed that patients in the upper quartile of PVC frequency (0.123–17.7 %) had a higher rate of cardiomyopathy, heart failure, and mortality.8 Although increased long-term presence of heart failure symptoms was noted even at low PVC frequencies, the range of PVC frequencies at which increased cardiomyopathy and mortality were seen was quite large and it is not clear based on this study which specific patients warrant closer monitoring or more aggressive therapy. Furthermore, to what extent PVCs represented a reversible etiology of subsequent clinical events in this cohort versus a marker of the severity of another underlying process remains to be seen. The majority of data suggest that patients with low to moderate PVC burdens and without structural heart disease will have a benign clinical course, with treatment focussed on symptom management.9 In patients with very frequent PVCs, the risk for development as well as the reversibility of PVC-induced cardiomyopathy is well established. Risk factors for development of cardiomyopathy include long-term exposure to very frequent PVCs. In one study, patients with a PVC burden >24 % were found to be at a particularly high risk of developing a PVC-induced cardiomyopathy, but the presence of cardiomyopathy was seen even with a PVC burden of 10 %.10 The mechanisms for developing PVC-induced cardiomyopathy are likely multifactorial and not completely understood but may at least partially be explained by ventricular dysynchrony caused by the PVCs. Other factors associated with a higher risk of developing cardiomyopathy include longer duration of exposure to PVCs, asymptomatic status, epicardial PVC origin, increased QRS duration of the PVCs, interpolated PVCs, and lack of circadian PVC variation.11–14 There is also evidence to suggest that men may have a slightly higher risk of developing PVCinduced cardiomyopathy than women.15 Although patients with PVCinduced cardiomyopathy are certainly at risk of developing significant heart failure symptoms, whether they are at the same risk for SCD as other patients with ischemic or other forms of cardiomyopathy is not clear.

The occurrence of SCD in patients with idiopathic PVCs is low, although difficult to quantitate due to its rarity. Patients with such a presentation should be screened for occult cardiac disease such as sarcoidosis or arrhythmogenic right ventricular dysplasia. When PVCs are documented to trigger sustained ventricular arrhythymias, ablation may be effective in eliminating or reducing the PVCs and subsequent arrhythmias.16 When polymorphic ventricular tachycardia or ventricular fibrillation is documented, an ICD is also indicated.17 In other patients, the decision to implant an ICD should consider various clinical parameters including documentation of clinical ventricular tachycardia, left ventricular function, inducibility of ventricular tachycardia during electrophysiology study, success of catheter ablation, and presence of structural heart disease by advanced imaging.

Presentation and Diagnostic Evaluation

The two most common indications for therapy to reduce or eliminate PVCs are symptomatic improvement and reversal of a cardiomyopathy.17 Symptoms can vary greatly and be a result of individual PVCs or the cumulative hemodynamic effect of frequent PVCs. Symptoms from individual PVCs can be from the PVCs themselves, a following compensatory pause, or a subsequent hypercontractile beat. These symptoms can include palpitations, chest pain, dyspnea, and lightheadedness. When symptoms are due to the cumulative hemodynamic effect of frequent PVCs, they can range from mild fatigue or dyspnea with exertion to significant heart failure with or without left ventricular dysfunction. Less common scenarios where PVC elimination may be pursued include PVCs limiting adequate biventricular pacing in patients with cardiac resynchronization therapy and patients in whom PVCs are implicated in triggering sustained ventricular arrhythmias.

In patients with frequent symptoms or frequent PVCs noted by 12-lead EKG, initial workup should include a 24–48-h Holter monitor and an echocardiogram. EKG monitoring can provide symptom correlation and identify PVC frequency. Twelve-lead Holter monitors are particularly useful in identifying the number of PVC foci. An echocardiogram should be used to evaluate ventricular function and dimensions as well as search for any other structural abnormalities. An initial search for secondary etiologies should be pursued and PVCs secondary to other cardiac or metabolic abnormalities may be reduced or eliminated with therapy addressing the underlying cause. Patients with symptoms on exertion should also have an exercise stress test including 12-lead EKG analysis. A positive stress test or symptoms consistent with ischemia, particularly in a patient with coronary risk factors, may prompt a coronary angiogram. While there are no specific criteria for obtaining a cardiac MRI, these are often obtained when it is necessary to further evaluate abnormalities detected on echocardiogram or in patients where symptoms or other findings suggest the potential presence of structural abnormalities not definitively evaluated by echocardiogram.

There is little data on the appropriate management of asymptomatic patients with very frequent PVCs (>10–20 %) without evidence of ventricular dysfunction or dilation. These patients are at risk for future development of cardiomyopathy, but whether prophylactic therapy is warranted is not clear. At a minimum, these patients should be followed regularly with periodic assessment of cardiac function.

Many patients with symptomatic PVCs without structural heart disease can be initially managed by their primary care physician. When advanced therapy such as antiarrhythmics or catheter ablation is necessary, or the presence of cardiomyopathy or other structural heart disease is present or suspected, referral to a cardiologist or cardiac electrophysiologist is appropriate.

Treatment

When behavioral triggers are identified, initial management may include an attempt to limit or eliminate these triggers. Although most patients do not experience a significant PVC reduction with behavioral modification such as reducing moderate caffeine, alcohol, or tobacco consumption,18,19 the secondary benefits of lifestyle modification can justify this as an initial strategy.

Pharmacotherapy

Initial pharmacotherapy for idiopathic PVCs usually consists of beta blockers or calcium channel blockers.17 The overall efficacy of these agents in eliminating PVCs is poor, with reported rates of 10–24 %;20–22 however, additional patients can experience an alleviation of symptoms even without significant PVC elimination. Despite the low efficacy, beta blockers and calcium channel blockers remain the most common initial treatment modalities as risks with these medications are generally low. Beta blockers may also be indicated in patients with evidence of cardiomyopathy.

Antiarrhythmic drugs to treat PVCs are more effective than beta blockers or calcium channel blockers, with a reported decease in PVC frequency and associated symptoms in 15–65 % of patients.20,23,24 Although efficacy is improved, this must be weighed against the potential risks and side effects of long-term exposure to antiarrhythmic medication. Antiarrhythmic therapy remains a useful option for patients refractory to other pharmacologic treatment, particularly those that are not ideal ablation candidates or have a preference for medical therapy.

Catheter Ablation

In appropriate patients, catheter ablation can offer the highest efficacy in the management of frequent PVCs. Factors that may favor attempts at ablation include a high frequency of PVCs, limited PVC foci, and favorable PVC locations. Ablation may be the preferred approach in patients with PVC-induced cardiomyopathy given the robust data showing favorable outcomes in these patients following ablation.

In one large-scale multicenter study, 1,185 patients referred for catheter ablation of frequent PVCs had a single procedural success rate of 84 %. Following an average of 1.3 ablations, 73 % of patients remained off antiarrhythmic drugs and maintained at least an 80 % PVC reduction at a mean follow-up of 1.9 years (Figure 1).15 Factors associated with a greater likelihood of success included right ventricular outflow tract origin and fewer PVC foci. The overall major complication rate in that study was 2.4 %, with access-related complications being the most common, and no procedural mortality observed.

The reversibility of PVC-induced cardiomyopathy following successful ablation has been well established, with normalization of ejection fraction being reported in >80 % of patients undergoing successful ablation and at least some improvement in ejection fraction in 85 % of all patients with cardiomyopathy attempting ablation.15,25 It is also important to recognize that PVCs can contribute to a pre-existing cardiomyopathy from other causes and an improvement in ejection fraction following successful PVC ablation can be observed in these patients.26

Figure 1: Acute and long-term success rates after ablation of premature ventricular complexes

Open in new tab
Open ppt

Summary

Most patients with PVCs in the absence of structural heart disease have a benign clinical course and can be treated based on symptoms. Patients with frequent idiopathic PVCs are at a higher risk for development of cardiomyopathy and heart failure. Treatment modalities to eliminate or reduce PVC burden include pharmacotherapy and catheter ablation. In the case of PVC-induced cardiomyopathy, successful PVC elimination by ablation usually normalizes or significantly improves cardiac function. In asymptomatic patients with very frequent PVCs and preserved cardiac function, regular follow-up and monitoring of cardiac function is warranted.

References
  1. Hiss RG, Lamb LE. Electrocardiographic findings in 122,043 individuals. Circulation 1962;25:947–61.
    Crossref | PubMed
  2. Hinkle LE, Carver ST, Stevens M. The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middleaged men. Am J Cardiol 1969;24:629–50.
    Crossref | PubMed
  3. Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term followup of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985;312:193–7.
    Crossref | PubMed
  4. Lerman BB, Belardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMPmediated triggered activity. Circulation 1986;74:270–80.
    Crossref | PubMed
  5. He W, Lu Z, Bao M, Yu L, et al. Autonomic involvement in idiopathic premature ventricular contractions. Clin Res Cardiol 2013;102:361–70.
    Crossref | PubMed
  6. Kostis JB, Byington R, Friedman LM, et al. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. J Am Coll Cardiol 1987;10:231–42.
    Crossref | PubMed
  7. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.
    Crossref | PubMed
  8. Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol 2015;66:101–9.
    Crossref | PubMed
  9. Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009;95:1230–7.
    Crossref | PubMed
  10. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865–9.
    Crossref | PubMed
  11. Bas HD, Baser K, Hoyt J, et al. Effect of circadian variability in frequency of premature ventricular complexes on left ventricular function. Heart Rhythm 2016;13:98–102.
    Crossref | PubMed
  12. Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012;9:1460–4.
    Crossref | PubMed
  13. Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm 2011;8:1046–9.
    Crossref | PubMed
  14. Yokokawa M, Kim HM, Good E, et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012;9:92–5.
    Crossref | PubMed
  15. Latchamsetty RY, Morady M, Kim F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol 2015;1:116–23.
    Crossref
  16. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol 2009;54:522–8.
    Crossref | PubMed
  17. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm 2014;11:e166–96.
    Crossref | PubMed
  18. DeBacker G, Jacobs D, Prineas R, et al. Ventricular premature contractions: a randomized non-drug intervention trial in normal men. Circulation 1979;59:762–9.
    Crossref | PubMed
  19. Prineas RJ, Jacobs DR, Crow RS, Blackburn H. Coffee, tea and VPB. J Chronic Dis 1980;33:67–72.
    Crossref | PubMed
  20. Stec S, Sikorska A, Zaborska B, et al. Benign symptomatic premature ventricular complexes: short- and long-term efficacy of antiarrhythmic drugs and radiofrequency ablation. Kardiol Pol 2012;70:351–8.
    PubMed
  21. Withagen AJ, Corbeij HM, Huige MC, et al. Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring. Drugs 1989;38(Suppl 2):67–9.
    Crossref | PubMed
  22. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J 2002;144:e10.
    Crossref | PubMed
  23. Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. Circulation 1995;92:1517–25.
    Crossref | PubMed
  24. Kubac G, Klinke WP, Grace M. Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. Can J Cardiol 1988;4:355–9.
    PubMed
  25. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007;4:863–7.
    Crossref | PubMed
  26. Sarrazin JF, Labounty T, Kuhne M, et al. Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fraction. Heart Rhythm 2009;6:1543–9.
    Crossref | PubMed